HOME >> BIOLOGY >> NEWS
Researchers identify cell, genetic environment behind nerve-tissue tumors that lead to cancer

DALLAS May 3, 2002 Researchers at UT Southwestern Medical Center at Dallas believe they are hot on the trail of a way to prevent benign tumors that attack the nervous system and can be precursors to terminal cancer.

The research, published in todays edition of Science, reveals that tumors in neurofibromatosis 1 (NF-1) patients form out of a particular type of cell, the Schwann cell. Neurofibromatosis, also known as von Recklinghausen disease, is a genetic disorder that causes benign tumors to form on the nerves, skin and internal organs.

Neurofibromatosis is the most common neurological disorder caused by a single gene, and there are two distinct forms: NF-1, which affects multiple organ systems, including the central and peripheral nervous systems, and is present in about 1 in 3,500 people worldwide; and NF-2, which affects only the vestibular nerve, a cranial nerve related to hearing and balance, and the membranes around the brain and spinal cord. NF-2 is present in about 1 in 40,000 people worldwide.

The benign tumors, called neurofibromas, develop into malignant tumors, called neurofibrosarcomas, in 10 percent to 15 percent of NF-1 patients. The malignant tumors do not respond well to currently available treatments.

The new research describes genetically permissive and restrictive environments for NF-1 tumor development. The tumors grow in a permissive environment, but they are nonexistent when the environment is restrictive, researchers say.

Dr. Yuan Zhu, instructor in the Center for Developmental Biology and lead author of the study, said the findings could lead to a new approach to combating NF-1. Zhu has been studying neurofibromatosis since 1995, when as a graduate student he joined the lab of Dr. Luis Parada, director of the Center for Developmental Biology and senior author of the paper.

The focus has always been on attacking the tumor cells, Zhu said. But in our findings, killing the tumor cells is not t
'"/>

Contact: Wayne Carter
Wayne.Carter@UTSouthwestern.edu
214-648-3404
UT Southwestern Medical Center
2-May-2002


Page: 1 2 3

Related biology news :

1. Researchers determine genetic cause of Timothy syndrome
2. Researchers find color sensitive atomic switch in bacteria
3. Researchers identify protein promoting vascular tumor growth
4. Researchers devise potent new tools to curb ivory poaching
5. Researchers create nanotubes that change colors, form nanocarpet and kill bacteria
6. Researchers ID chlorophyll-regulating gene
7. Researchers develop fast track way to discover how cells are regulated
8. Researchers identify distinctive signature for metastatic prostate cancer
9. Researchers report new gene test for isolated cleft lip and palate
10. Researchers discover why mutant gene causes colon cancer
11. Researchers identify the genomes controlling elements

Post Your Comments:
(Date:7/24/2014)... (July 24, 2014) Scientists at The New ... one step closer to creating a viable cell ... own cells. , For the first time, ... lines from skin samples of patients with primary ... accelerated protocol to induce these stem cells into ...
(Date:7/24/2014)... many sobering examples of how wildlife loss leads to ... co-authored by Wildlife Conservation Society (WCS) Health & ... Golden, calls for an interdisciplinary approach to tackle global ... supports about 15% of the world,s people and provides ... poor. It should come as no surprise that today,s ...
(Date:7/24/2014)... New York, NY - July 24, 2014 -- Keryx ... results from the long-term, randomized, active control Phase 3 ... ferric iron-based phosphate binder, for the treatment of hyperphosphatemia ... The PERFECTED study (PhosphatE binding and iRon delivery with ... the Journal of the American Society of Nephrology ...
Breaking Biology News(10 mins):NYSCF scientists one step closer to cell therapy for multiple sclerosis patients 2New study draws links between wildlife loss and social conflicts 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4
(Date:7/24/2014)... 24, 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") ... active control Phase 3 study of Zerenex (ferric citrate), ... the treatment of hyperphosphatemia in patients with end-stage renal ... and iRon delivery with FErric CiTrate in EsrD) was ... American Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... Tenn., July 24, 2014 -- A novel combination of ... Department of Energy,s Oak Ridge National Laboratory an unprecedented ... its unusual physical and electrochemical properties. , The ... oxygen affects the surface of a perovskite manganite, a ... The new avenue to understand surface behavior could benefit ...
(Date:7/24/2014)... CA (PRWEB) July 24, 2014 ... the Global Supply Chain of the biotech industry. ... SCM Innovation Awards, brought to you by the ... global organization of supply chain management professionals for ... given to stakeholders of the Biotech industry – ...
(Date:7/24/2014)... Calif. , July 24, 2014  Now available ... to home. Rehealth Regenerative Therapies , located in ... and other physically active people a new health option: ... Regardless of age, countless patients suffer from joint ... activities, such as muscle tears, torn rotator cuff, tennis ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4ORNL study reveals new characteristics of complex oxide surfaces 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3
Cached News: